Clinical Trial Update: Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart Failure (NYHA Class III-IV) [Phase 3]

View source ↗

Summary

Update on an ongoing Phase 3 trial evaluating HiCM-188, an induced pluripotent stem cell-derived cardiomyocyte injection, for advanced heart failure; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• HiCM-188 (Human induced pluripotent stem cell-derived cardiomyocyte injection)

Snippet

Sponsor: HELP Therapeutics Co., Ltd. | Conditions: Heart Failure | Phase 3 | Status: RECRUITING